R&D news R&D ability Basic Reactions  

       
  Hichem's R&D:

Research Terms:
Senior Researchers : 12
Chemical-engineers over 10-year's experience in scale-up: 8

Analysis Equipments:
Supported by Shanghai Institute of Pharmaceutical Indsutry ,
we have complete normal equipment for our research like
IR, UV, NMR, HNMR MS, Polarimeter
HPLC, HPLC-MS, Preparative HPLC
CGC, GC-MS
TLC Scanner

Professional Advantages in pharmaceuticals:
1. Broad background in drug design of novel enzyme inhibitors and receptor antagonists related to research areas of b-Lactam antibiotics, cardiovascular, AIDS-virus and central nervous systems as new drug candidates.
2. The pre-clinic trials of anti-cerebral ischemic agents, novel non-opium analgesics and new type of anti-depressant in progress.
3. Expertise in synthesis of chiral intermediates by using chemical and enzymic resolution or asymmetric synthesis techniques.
4. Extensive experiences in synthesis of Isoflavone compounds, Boron derivatives and Porphyrin Analogues.
5. Liquid-phase synthesis of the polypeptides in scale-up.
6. Pilot-scale production and process optimization of key intermediates.

Experience for following projects:
- HIV enzyme depressor for new drug of anti-aids
- antisense nucleic acid for new drugs of anti-molecule gene disease
- isoflavone compounds applying in anti-cancer and nerve center system
- anti-cerebral-ischemia apoplexy
- anti-aged-imbecile, anti-melancholia and nerve center anodyne
- New drumnone-aspirin anodyne
- anti-angina and hypertension like Diltiazem HCl
- New drug AG for anti-haematoblast-manifold
- Grade III new drug FV for anti terminal galactophore cancer
- Grade III new drug DT for anti-retch from chemical-cure
- SPP for anti-Parkinsons¡¯s disease
- Grade III new drug for anti gynecological infection


Copyright 2008 Hichem Industry Ltd. Allright reserved.